MusclePharm (MSLPQ) 10-Q 5 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	2-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'MusclePharm Corp	'
Entity Central Index Key	'0001415684	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'MSLP	'
Entity Common Stock, Shares Outstanding	'	10,612,912
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash	$3,316,178	$5,411,515
Cash - restricted	2,500,630	2,500,014
Debt securities	215,000	259,715
Accounts receivable - net	19,634,074	13,741,180
Derivative instrument	0	119,248
Inventory - net	16,654,140	15,772,368
Prepaid giveaways	1,290,751	1,177,539
Prepaid stock compensation	3,064,230	3,023,717
Prepaid sponsorship fees	455,111	1,145,161
Prepaid expenses	1,606,235	1,335,218
Other assets	262,579	40,805
Total current assets	48,998,928	44,526,480
Property and equipment - net	5,463,287	2,613,584
Prepaid stock compensation	3,989,065	4,718,238
Intangible assets - net	7,025,644	155,165
Other assets	140,738	144,229
Total assets	65,617,662	52,157,696
Current Liabilities:	'	'
Accounts payable	24,290,625	26,605,588
Accrued liabilities	3,188,048	2,053,101
Debt - net	59,600	62,502
Line of credit	2,500,000	2,500,000
Derivative liabilities	663,096	1,147,330
Total current liabilities	30,701,369	32,368,521
Long Term Liabilities:	'	'
Other	118,277	54,639
Total Liabilities	30,819,646	32,423,160
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Common Stock, $0.001 par value; 100,000,000 shares authorized, 10,519,833 and 9,259,411 issued and 10,349,912 and 9,089,490 outstanding	10,520	9,260
Treasury Stock, at cost; 169,921 and 169,921 shares	-1,498,298	-1,498,298
Additional paid-in capital	115,395,134	103,064,901
Accumulated deficit	-79,091,183	-81,827,417
Accumulated other comprehensive loss	-18,289	-14,042
Total Stockholders' Equity	34,798,016	19,734,536
Total Liabilities and Stockholders' Equity	65,617,662	52,157,696
Series D Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Series D, Convertible Preferred Stock, $0.001 par value; 1,600,000 shares authorized, 1,500,000 shares issued and 131,500 outstanding	$132	$132

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Mar. 31, 2014	Dec. 31, 2013
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	10,519,833	9,259,411
Common Stock, shares outstanding	10,349,912	9,089,490
Treasury Stock, shares	169,921	169,921
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,600,000	1,600,000
Preferred stock, shares issued	1,500,000	1,500,000
Preferred stock, shares outstanding	131,500	131,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Sales - net	$50,209,454	$22,561,167
Cost of sales	32,336,385	14,396,406
Gross profit	17,873,069	8,164,761
Advertising and promotion	6,328,487	2,317,377
Salaries and benefits	5,366,806	1,248,459
Selling, general, and administrative	1,872,368	1,145,556
Research and development	1,096,946	90,129
Professional fees	784,574	4,084,720
Operating expenses	15,449,181	8,886,241
Income (loss) from operations	2,423,888	-721,480
Other income (expense)	'	'
Derivative expense	0	-96,913
Change in fair value of derivative liabilities	484,234	-6,044,643
Gain on settlement of accounts payable	5,499	276,985
Interest expense	-39,373	-780,320
Foreign currency transaction loss	-30,106	-5,610
Interest income	222,756	0
Unrealized loss on derivative instrument and debt securities	-386,103	0
Other income	87,600	10,000
Total other income (expense) - net	344,507	-6,640,501
Net income (loss) before taxes	2,768,395	-7,361,981
Income tax provision	-32,161	0
Net income (loss)	2,736,234	-7,361,981
Other Comprehensive Income (Loss)	'	'
Net change in Foreign currency translation	-4,247	-6,068
Total other comprehensive income (loss)	-4,247	-6,068
Total comprehensive income (loss)	$2,731,987	($7,368,049)
Net income (loss) per share available to common stockholders - basic (in dollars per share)	$0.27	($1.78)
Net income (loss) per share available to common stockholders - diluted (in dollars per share)	$0.23	($1.78)
Weighted average number of common shares outstanding during the period - basic (in shares)	10,307,350	4,128,679
Weighted average number of common shares outstanding during the period - diluted (in shares)	11,951,923	4,128,769

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities:	'	'
Net income (loss)	$2,736,234	($7,361,981)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation	313,934	161,341
Amortization of prepaid stock compensation	795,318	121,253
Amortization of debt issue costs	0	335,433
Amortization of prepaid sponsorships and endorsements	1,657,652	678,206
Amortization of intangible assets	285,183	0
Amortization of employee and executive stock awards	2,376,136	36,978
Accretion of conversion option on convertible note receivable	-222,140	0
Gain on settlement of accounts payable	-5,499	-276,985
Gain on disposal of equipment	-1,800	0
Derivative expense	0	96,913
Change in fair value of derivative liabilities	-484,234	6,044,643
Unrealized loss on debt security	60,000	0
Unrealized loss on derivative assets	326,103	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	-5,086,682	-4,726,062
Prepaid and other	-879,450	-13,280
Inventory and prepaid giveaways	-153,985	9,016
Increase (decrease) in:	'	'
Accounts payable	-2,300,764	1,615,958
Accrued liabilities	-264,445	62,451
Other liabilities	63,638	0
Net Cash Used In Operating Activities	-784,801	-3,216,116
Cash Flows From Investing Activities:	'	'
Purchase of property and equipment	-1,304,571	-216,267
Proceeds from disposal of property and equipment	1,800	1,694
Change in restricted cash balance	-616	9,147
Purchase of trademark	0	-20,000
Net Cash Used In Investing Activities	-1,303,387	-225,426
Cash Flows From Financing Activities:	'	'
Repayment of debt	-2,902	-4,390,386
Repurchase of common stock (treasury stock)	0	-103,537
Proceeds from issuance of preferred stock	0	12,000,000
Proceeds from issuance of common stock and warrants	0	5,977,499
Stock issuance costs	0	-1,560,956
Net Cash (Used In) Provided by Financing Activities	-2,902	11,922,620
Effect of exchange rates on cash and cash equivalents	-4,247	1,849
Net (decrease) increase in cash	-2,095,337	8,482,927
Cash at beginning of period	5,411,515	0
Cash at end of period	3,316,178	8,482,927
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	35,821	501,165
Cash paid for taxes	83,452	0
Supplemental disclosure of non-cash investing and financing activities:	'	'
Stock issued for future services - third parties	0	1,628,085
Warrants issued in conjunction with equity issuances	0	8,175,459
Stock issued to settle accounts payable and accrued expenses- third parties	0	5,364,947
Stock issued for asset purchase (See Note 16 - Biozone Acquisition)	9,840,000	0
Stock issued for executive and board compensation	$115,358	$114,912

Nature_of_Operations_and_Basis

Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Note 1: Nature of Operations and Basis of Presentation
	Nature of Operations
	MusclePharm Corporation is a scientifically driven, performance lifestyle Company that develops, manufactures, markets and distributes branded nutritional supplements. We were incorporated in Nevada in 2006.  As used in this report, the terms the “Company”, “we”, “our”, “MusclePharm”, or “MP” refer to MusclePharm Corporation and its predecessors, subsidiaries and affiliates, unless the context indicates otherwise. Our principal executive offices are located in Denver, Colorado.
	Basis of Presentation
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), as amended for interim financial information.
	The financial information as of December 31, 2013 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. The unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K, which contains the audited financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the years ended December 31, 2013 and 2012.
	Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the three months ended March 31, 2014 are not necessarily indicative of results for the full fiscal year.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2: Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries MusclePharm Canada Enterprises Corp (“MusclePharm Canada”) and Biozone Laboratories, Inc. (“Biozone”). MusclePharm Canada began operations in April 2012, and Biozone began operations in January 2014. All intercompany accounts and transactions have been eliminated upon consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. At March 31, 2014 and December 31, 2013, the Company had no cash equivalents.
	The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.  At March 31, 2014 and December 31, 2013, we had two bank accounts that exceeded the federally insured limit.
	Restricted Cash
	The Company segregates cash that is restricted in its use based on contractual provisions from unrestricted cash and cash equivalent balances. See Note 8(A) for further discussion on our March 31, 2014 restricted cash balance.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet utilized by period end.
	Management performs ongoing evaluations of the Company’s customers’ financial condition and generally does not require collateral. Some international customers are required to pay for their orders in advance of shipment. Management reviews accounts receivable quarterly and reduces the carrying amount by a valuation allowance that reflects management’s best estimate of amounts that may not be collectible. Allowances, if any, for uncollectible accounts receivable are determined based upon information available and historical experience. Bad debt expense recognized as a result of our valuation allowance is classified under General and administrative expense in the Consolidated Statement of Operations.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices. The Company’s finance department contacts customers with past due balances to request payment.
	Accounts receivable consisted of the following at March 31, 2014 and December 31, 2013:
			As of March 31,			As of December 31,
			2014			2013
	Accounts receivable		$	20,274,972		$	14,830,487
	Less: allowance for discounts			-535,621			-1,060,000
	Less: allowance for doubtful accounts			-105,277			-29,307
	Accounts receivable – net		$	19,634,074		$	13,741,180
	At March 31, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable with customers:
	Customer		As of March 31, 2014				As of December 31, 2013
	A			22	%			16	%
	Bodybuilding.com (related party – See Note 14)			8	%			14	%
	C			6	%			24	%
	Inventory
	Inventory is valued at the lower of cost or market value. Product-related inventory for MusclePharm and MusclePharm Canada is maintained using the First-In First-Out method, and inventory for Biozone is maintained using the average cost method. To estimate any necessary obsolescence or lower-of-cost-or-market adjustments, various assumptions are made in regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand, production planning and market conditions.
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory sample items which are given away to aid in promotion of the brand.
	Prepaid Sponsorship and Endorsement Fees
	Prepaid sponsorship and endorsement fees represent fees paid in connection with Company sponsorships of certain events and trade shows as well as prepaid athlete endorsement fees, which are expensed over the period the fees are earned. A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts.  Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions.  Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract.  Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
	Prepaid Stock Compensation
	Prepaid stock compensation represents amounts paid with stock for future contractual benefits to be received. The Company amortizes these contractual benefits over the life of the contracts using the straight-line method.
	Prepaid Expenses
	Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include legal retainers, print advertising, insurance and service contracts requiring up-front payments.
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in the Statements of Operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment. We review our property and equipment for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our property and equipment to be impaired during the three months ended March 31, 2014 or 2013.
	Debt Securities
	The Company classifies its investment securities as either held-to-maturity, available-for-sale or trading. The Company’s debt securities are classified as trading securities and are carried at fair value with changes recognized through net income. See Note 6 for further discussion of the Company’s debt securities.
	Accrued Liabilities
	Accrued liabilities consist of amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.
	Debt
	The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 8 for further disclosure of debt liabilities.
	Derivatives
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses Black-Scholes or lattice option-valuation models. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
	Once derivative instruments are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using a Black-Scholes or lattice option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid-in capital if redeemed or through earnings if forfeited or expired.
	Share-Based Payments
	Generally, all forms of share-based payments, including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.
	Revenue Recognition
	The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all of our Canadian sales, which represent 2% of total sales, recognition occurs upon shipment.
	The Company has determined that advertising related credits that were granted to customers fell within the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives). The guidance indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
	The Company records sales allowances and discounts as a direct reduction of sales. The Company grants volume incentive rebates to certain customers based on contractually agreed upon percentages once certain thresholds have been met. These volume incentive rebates are recorded as a direct reduction to sales.
	Sales for the three months ended March 31, 2014 and 2013 are as follows:
			Three Months Ended March 31,
			2014			2013
	Gross Sales		$	56,705,286		$	24,924,036
	Discounts			-6,495,832			-2,362,869
	Sales – Net		$	50,209,454		$	22,561,167
The Company has an informal 7-day right of return for products. There were nominal returns under the Company’s informal right of return policy for the three months ended March 31, 2014 and 2013.
Significant Customers
For the three months ended March 31, 2014 and 2013, the Company had the following concentrations of revenues with customers:
		Three Months Ended March 31,
Customer		2014		2013
Bodybuilding.com (related party – See Note 14)		15	%	33	%
B		14	%	11	%
A loss of either of these customers could have a material adverse impact on the Company.
Discounts and Sales Allowances
We offer various discounts and sales allowances for volume rebate programs, product promotions, early payment remittances, and other discounts and allowances. We accrue for sales discounts and allowances over the period they are earned. Because of the inherent uncertainty surrounding volume rebate programs and product promotions that are based on sales thresholds, actual results could generate liabilities greater or less than the recorded amounts. Sales discounts and allowances for the three months ended March 31, 2014 and 2013 were $6.5 million, or 11% of gross sales, and $2.4 million of 9% of gross sales, respectively.
Cost of Sales
Cost of sales for MusclePharm and MusclePharm Canada represent costs directly related to the production, manufacturing and freight of the Company’s products purchased from third party manufacturers. For products produced by Biozone, cost of sales consists of costs for raw material, direct labor, freight expenses, and other supply and equipment rental expenses used to manufacture products.
Significant Vendors
The Company uses four non-affiliated principal manufacturers for the components of our products. We have an agreement in place with our primary manufacturer, which is in place to support our growth and ensure consistency in production and quality. During the three months ended March 31, 2014, our primary manufacturer accounted for approximately 54% of our product purchases and the next largest manufacturer accounted for 44% of product purchases. For the three months ended March 31, 2013, our primary manufacturer accounted for 97% of our product purchases.
Shipping and Handling
We ship customer orders from our distribution center in Franklin, Tennessee. The facility is operated with the Company’s equipment and employees, and all inventory is owned by the Company. Shipments to customers from our distribution center are recorded as a component of cost of sales.
The Company also uses a manufacturer in New York to manufacture one of the Company’s products. These orders are typically large and heavy and are drop shipped directly to our customers at the time of order. Costs associated with these shipments are recorded in cost of sales.
For Canadian sales, the product is shipped from our Canadian warehouse to our customers. Costs associated with the shipments are recorded in cost of sales.
Advertising
Advertising and promotion expenses include digital and print advertising, trade show events, athletic endorsements and sponsorships, and promotional giveaways.  Advertising expenses are recognized in the month that the advertising appears while costs associated with trade show events are expensed when the event occurs.  For major trade shows, the expenses are recognized within the calendar year over the period in which we recognize revenue associated with sales generated at the trade show. Costs related to promotional giveaways are expensed when the product is either given out at a promotional event or shipped to the customer.
A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts.  Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions.  Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract.  Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
Some of the contracts provide for contingent payments to endorsers or athletes based upon specific achievement in their sports (e.g. winning a championship).  The Company records expense for these payments when the endorser achieves the specific achievement.
Advertising expense for the three months ended March 31, 2014 and 2013, are as follows:
		Three Months Ended March 31,
		2014			2013
Advertising and promotion		$	6,328,487		$	2,317,377
Income Taxes
Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Beginning with the adoption of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes, (included in FASB ASC Subtopic 740-10, Income Taxes — Overall), the Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three months ended March 31, 2014 and 2013.
Earnings (Loss) Per Share
Basic net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
The Company uses the “treasury stock” method to determine whether there is a dilutive effect of outstanding option and warrant contracts. For the three months ended March 31, 2013 the Company reflected net loss and a dilutive net loss, and the effect of considering any common stock equivalents would have been anti-dilutive for the period. Therefore, separate computation of diluted earnings (loss) per share is not presented for the three months ended March 31, 2013.
The Company has the following common stock equivalents as of March 31, 2014 and 2013, respectively:
		As of March 31,
		2014		2013
Stock options (exercise price – $425/share)		472		670
Warrants (exercise price – $4 - $1,275/share)		263,089		687,839
Employee and director unvested shares		1,381,573		86,275
Total common stock equivalents		1,645,134		774,784
The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three months ended March 31, 2014 and 2013, respectively:
		Three months ended
		March 31,
		2014			2013
Net income (loss)		$	2,736,234		$	-7,361,981
Weighted average number of common shares outstanding			10,307,350			4,128,679
Incremental shares from the assumed exercise of dilutive agreements			1,644,573			-
Diluted common shares outstanding			11,951,923			4,128,679
Earnings (loss) per shares - basic		$	0.27		$	-1.78
Earnings (loss) per shares - diluted		$	0.23		$	-1.78
Foreign Currency
MusclePharm began operations in Canada in April 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are exchanged in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into the U.S. Dollar, which is the reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the period and the assets and liabilities at the end of period rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income and expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and held in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.
Reclassification
The Company has reclassified certain prior period amounts to conform to the current period presentation. These reclassifications were for presentation purposes and had no effect on the financial position, results of operations, or cash flows for the periods presented.
Recent Accounting Pronouncements
In March 2013, the FASB issued ASU 2013-05, which indicates that the entire amount of a cumulative translation adjustment (CTA) related to an entity’s investment in a foreign entity should be released when one of the following occur:
	⋅	Sale of a subsidiary or group of net assets within a foreign entity and the sale represents the substantially complete liquidation of the investment in the foreign entity.
	⋅	Loss of a controlling financial interest in an investment in a foreign entity
	⋅	Step acquisition for a foreign entity
The ASU does not change the requirement to release a pro rata portion of the CTA of the foreign entity into earnings for a partial sale of an equity method investment in a foreign entity. ASU 2013-5 is effective for fiscal years (and interim periods within those fiscal years) beginning on or after December 15, 2013. The adoption of this pronouncement did not have a material impact on our consolidated financial statements.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 3: Property and Equipment
	Property and equipment consisted of the following at March 31, 2014 and December 31, 2013:
		As of March 31, 2014		As of December 31, 2013		Estimated Useful Life
	Leasehold improvements	$	3,205,922	$	619,159	From 20 to 182 months
	Furniture, fixtures and equipment		2,059,778		1,849,462	From 3 to 5 years
	Manufacturing and lab equipment		1,183,168		-	From 2 to 20 years
	Vehicles		444,065		442,300	From 2 to 5 years
	Displays		33,683		33,683	5 years
	Website		11,462		11,462	3 years
	Construction in process		190,373		1,018,509
	Total		7,128,451		3,974,575
	Less: Accumulated depreciation		-1,665,164		-1,360,991
		$	5,463,287	$	2,613,584

Inventory

Inventory	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 4: Inventory
	Inventory consisted of the following at March 31, 2014 and December 31, 2013:
		March 31, 2014		December 31, 2013
	Raw materials inventory	$	661,026	$	-
	Work in process inventory		16,411		-
	Finished goods inventory		16,077,964		16,001,515
	Inventory reserve		-101,261		-229,147
	Total inventory - net	$	16,654,140	$	15,772,368
	Included in the table above is $16,039,948 of finished goods inventory that has been purchased from third party manufacturers. The Company reserves for obsolete and slow moving inventory based on the age of the product as determined by the expiration date.  Products within one year of their expiration dates are considered for reserve purposes.  Historically, we have had minimal returns, and any damaged packaging is sent back to the manufacturer for replacement.  The Company recorded a reserve for obsolete and slow moving inventory of $101,261 and $229,147 as of March 31, 2014 and December 31, 2013.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 5: Fair Value of Financial Instruments
	The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchical levels of inputs to measure fair value:
		⋅	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
		⋅	Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		⋅	Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.  The following are the major categories of assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):
			As of March 31,		As of December 31,
			2014		2013
	Assets
	Debt securities – FUSE convertible notes (Level 2)		$	215,000	$	259,715
	Derivative instruments – FUSE warrants (Level 2)			-		119,248
				215,000		378,963
	Liabilities
	Derivative liabilities - Series D shares (Level 2)		$	663,096	$	1,147,330
	The Company’s remaining financial instruments consisted primarily of accounts receivable, accounts payable and accrued liabilities, and debt. The Company’s debt approximates fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of March 31, 2014 and December 31, 2013, respectively, due to the short-term nature of these instruments.

Debt_Securities

Debt Securities	3 Months Ended
	Mar. 31, 2014
Investments, Debt and Equity Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	'
	Note 6: Debt Securities
	On November 7, 2013, the Company purchased, for an aggregate $200,000, a senior secured convertible promissory note from Fuse Science Inc.  (“Fuse”) (OTC:DROP) that matures 90 days from the date of issuance, and certain derivative instruments (Note 7), the value of which was recorded as a discount to the note to be accreted over the note’s term.  The promissory note bears interest at a rate of 10% per annum and is convertible at any time prior to the maturity date into 3,076,923 shares of Fuse common stock at the conversion rate of $0.065 per share. The Company’s ability to convert into Fuse common stock is restricted by a beneficial ownership limitation of 9.99% of the number of the common stock outstanding after giving effect to the issuance of common stock issuable upon conversion. On December 11, 2013, the Company amended the Fuse note and funded an additional $75,000 under the original terms of the note.
	On January 3, 2014, the Company renewed the combined $275,000 senior secured convertible promissory note from Fuse with a new maturity date of January 3, 2019 and convertible into 13,750,000 shares at a conversion rate $0.02 per share.
	The Company has classified this note as a Level 2 trading security and has used a Black-Scholes valuation model to determine the value of the conversion option and detachable derivative instrument.  Changes in the reported value of the note will be included as a component of net income.  Values of $206,855 and $174,574 attributable to the conversion option and derivative instruments, respectively, have been recorded as a discount to be accreted as interest income over the stated maturity of the note.  As of March 31, 2014, the entire discount has been accreted to interest income. See Note 18 for subsequent events related to the Fuse convertible note.
	The following table summarizes the Company’s debt securities activity for the three months ended March 31, 2014:
		Fuse Note
	Balance – December 31, 2013	$	259,715
	Redemption of note		-275,000
	Renewal of note		275,000
	Discount for value of conversion option		-206,855
	Accretion of net discount		222,140
	Unrealized loss on debt security		-60,000
	Balance – March 31, 2014	$	215,000

Derivative_Instruments

Derivative Instruments	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	Note 7: Derivative Instruments
	In conjunction with the purchase of the Fuse convertible promissory note as amended and discussed in Note 6, the Company received callable warrants to purchase up to 9,165,750 shares of Fuse at an exercise price of $0.065 per share with expiration dates of 5 years from the date of issuance. The initial value of the warrants was $174,574 and was recorded as a discount against the note. Upon renewal of the convertible note as discussed in Note 6, the Company recognized the conversion option of the convertible note as a derivative instrument with an initial value of $206,855, which was recorded as a discount against the note.
	The Company has classified the warrant and conversion option as a Level 2 fair value measurement, and used a Black-Scholes model to value the warrant and conversion option.  This model considers price volatility, time and risk.
	The following table summarizes the Company’s derivative asset activity for the three months ended March 31, 2014:
	Balance – December 31, 2013	$	119,248
	Fair value of conversion option at renewal		206,855
	Unrealized loss		-326,103
	Balance – March 31, 2014	$	-
	See Note 18 for subsequent events related to the Fuse warrants.

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 8: Debt
	At March 31, 2014 and December 31, 2013, debt consists of the following:
			As of March 31, 2014		As of December 31, 2013
	Revolving line of credit		$	2,500,000	$	2,500,000
	Auto loan - secured			-		2,902
	Unsecured debt			59,600		59,600
	Total debt			2,559,600		2,562,502
	Less: current portion			-2,559,600		-2,562,502
	Long term debt		$	-	$	-
	Debt in default of $59,600 and $59,600 at March 31, 2014 and December 31, 2013, respectively, is included as a component of short-term debt. Debt in default is related to certain convertible notes issues in 2012 and prior where the notes were never converted to common stock or principal repaid. The Company is in the process of contacting the note holders and negotiating settlement of the notes.
		(A)	Revolving Line of Credit
	On December 24, 2013, the Company entered into a revolving line of credit with U.S. Bank, N.A. in the amount of $2,500,000. The line of credit matures on September 15, 2014 and accrues interest at prime plus 2%, which is payable monthly. The interest rate at March 31, 2014 was 5.25%. The note is secured by a $2,500,000 savings account held at U.S. Bank, N.A. and is shown as restricted cash in the Consolidated Balance Sheets.
	(B) Unsecured Debt
	Unsecured debt consisted of the following activity and terms:
	Balance - December 31, 2013		$	59,600
	Repayments			-
	Balance – March 31, 2014		$	59,600
	(C) Vehicle Loan
	Vehicle loan account consisted of the following activity and terms:
					Interest Rate		Maturity
	Balance - December 31, 2013		$	2,902	6.99	%	3 payments of $1,008
	Repayments			-2,902
	Balance – March 31, 2014		$	-

Derivative_Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Fair Value [Text Block]	'
	Note 9: Derivative Liabilities
	The Company identified conversion features embedded within Series D Preferred Stock issued in 2013. The Company has determined that the features associated with the embedded conversion option should be accounted for at fair value as a derivative liability as the Company could not determine if a sufficient number of shares would be available to settle all transactions.
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2013		1,147,330
	Fair value mark to market adjustment for equity instruments		-484,234
	Derivative liability – March 31, 2014	$	663,096
	The Company recorded the day one value of derivative contracts associated with the Series D preferred stock issuance against gross proceeds raised, and expensed immediately the remaining value of the derivative as it exceeded the gross proceeds of the offering. The Company recorded a derivative expense of $0 and $96,913 for the three months ended March 31, 2014 and 2013, respectively.
	The fair values at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2014:
			Commitment Date		Re-measurement Date
	Expected dividends		0	%	0	%
	Expected volatility		120	%	40	%
	Expected term:		1 year		1 year
	Risk free interest rate		0.14	%	0.13	%

Restricted_Stock_Units

Restricted Stock Units	3 Months Ended
	Mar. 31, 2014
Schedule Of Share Based Compensation Restricted Stock and Restricted Stock Units [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	Note 10: Restricted Stock Units
	In November 2012, the Company granted 129,413 restricted stock units through restricted stock unit agreements to certain executives. Each restricted stock unit represents a contingent right to receive one share of the Company’s common stock upon vesting. The value of this award at the grant date was $449,900 and will be amortized over the vesting periods such that each tranche of restricted stock units will be fully amortized at the date of vesting. The restricted stock units vest in one tranche of 43,137 on January 1, 2013 and two tranches of 43,138 shares on January 1, 2014 and December 1, 2014. As of March 31, 2014, 86,275 restricted stock units have vested and the unamortized portion of this award is $112,989.
	In June 2013, the Company approved a restricted stock award to certain key employees, officers and directors for 1,550,000 cumulative shares. The awarded shares were issued upon the award’s approval with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $17,065,500. Of these shares, the Company estimates that 1,500,200 shares will fully vest for a total value of $16,517,202. This amount will be amortized over the vesting periods such that each tranche’s estimated shares of restricted stock will be fully amortized at the dates of vesting. The Company will periodically review this estimate for reasonableness and make adjustments as appropriate. The award vests in two tranches with 17% vesting December 31, 2013 and the remaining 83% vesting December 31, 2015 with the exception of certain executives under employment agreements that terminate prior to December 31, 2015. These awards will be amortized over the remaining term of their employment agreements. As of March 31, 2014, 263,500 shares have vested and the unamortized portion of this award is $11,342,915.
	In December 2013, the Company granted the independent members of the Board of Directors a restricted stock grant of 19,364 shares as part of the annual director’s compensation plan. The awarded shares were issued upon the award’s approval with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $152,000, and will be amortized over the vesting periods. The restricted stock award will vest in three equal tranches on July 1, 2014, July 1, 2015, and July 1, 2016. As of March 31, 2014, no shares have vested and the unamortized portion of the awards was $113,998.
	On March 17, 2014, the Company granted the independent members of the Board of Directors a restricted stock grant of 48,856 shares as part of the annual director’s compensation plan. The awarded shares were issued upon the award’s approval with ownership rights to be conveyed upon vesting. The value of this award at the grant date was $320,007, and will be amortized over the service period, which is January 1 – December 31, 2014. The restricted stock award will vest in three equal tranches on March 17, 2014, March 17, 2015, and March 17, 2016. As of March 31, 2014, 16,284 shares have vested and the unamortized portion of the awards is $240,000.
	Total compensation expense for these awards recognized during the three months ended March 31, 2014 was $2,402,435 and is included in operating expenses.

Stockholders_Equity

Stockholders' Equity

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

'

Stockholders' Equity Note Disclosure [Text Block]

'

Note 11: Stockholders’ Equity

(A) Series D Convertible Preferred Stock

In January 2013, the Board of Directors authorized 1,600,000 shares of Series D convertible preferred stock. Between January 16, 2013 and February 4, 2013, the Company entered into separate subscription agreements with certain investors in connection with the offering, pursuant to which the Company sold an aggregate of 1,500,000 shares of Preferred Stock for aggregate gross proceeds of approximately $12 million. Pursuant to the Certificate of Designation of the Series D Convertible Preferred Stock filed with the Nevada Secretary of State on January 11, 2013 (the “Certificate of Designation”), each share of Preferred Stock is convertible into two shares of common stock, subject to adjustment as set forth in the Certificate of Designation.  During the three months ended March 31, 2014, no shares of Series D convertible preferred stock were converted into common stock. See Note 18 for subsequent events related to Series D stock conversion.

The shares of Series D have the following provisions:

⋅

Voting rights based on number of common shares of conversion option;

⋅

Initially no rights to dividends;

⋅

Liquidation rights entitle the receipt of net assets on a pro-rata basis; and

⋅

Convertible into 2 shares of common stock, subject to adjustment.

(B) Common Stock

During the three months ended March 31, 2014, the Company issued the following common stock:

Transaction Type

Quantity

Valuation

Range of Value

(#)

($)

per Share

($)

Executive/board of director compensation

60,422

265,325

3.48 – 8.70

Stock issued for Biozone asset purchase

1,200,000

9,840,000

8.2

Total

1,260,422

10,105,325

3.48 – 8.70

The fair value of all stock issuances above is based upon the quoted closing trading price on the date of issuance. See Note 16 for further details of the Biozone asset purchase.

(C) Stock Options

There was no stock option activity for the three months ended March 31, 2014.

(D) Stock Warrants

A summary of warrant activity for the Company for the three months ended March 31, 2014 is as follows:

Number of Warrants

Weighted Average Exercise Price

Balance at December 31, 2013

263,089

4.43

Granted

-

-

Exercised

-

-

Converted

-

-

Balance at March 31, 2014

263,089

4.43

Warrants Outstanding

Warrants Exercisable

Range of

Number

Weighted Average

Weighted Average

Number

Weighted

Intrinsic Value

Exercise Prices

Outstanding

Remaining

Exercise Price

Exercisable

Average

Contractual Life (in

Exercise Price

years)

$

$4 - 1,275

263,089

1

$

4.43

263,089

$

4.43

$

518,295

See Note 18 for subsequent events related to conversion of Series D warrants.

(E) Stock Repurchase Plan

On December 10, 2013, the Board of Directors approved a one year, $5 million stock repurchase plan allowing for the repurchase of up to $5,000,000 of MusclePharm common stock over a one year period. During the three month period ended March 31, 2014, no shares were repurchased under this plan.

Commitments_Contingencies_and_

Commitments, Contingencies and Other Matters	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 12: Commitments, Contingencies and Other Matters
	(A) Operating Lease
	The Company accounts for leases as operating or capital based on the criteria set forth in ASC 840-10-25-1. The Company has various non-cancelable operating leases with terms expiring through 2029.
	Future minimum annual lease payments for the above leases are approximately as follows:
	Years Ending December 31,
	2014 (9 months)	$	967,816
	2015		868,844
	2016		355,916
	2017		291,528
	2018		291,528
	Thereafter		3,206,808
	Total minimum lease payments	$	5,982,440
	Rent expense for the three months ended March 31, 2014 and 2013, was $297,497 and $151,219, respectively.
	(B) Capital Leases
	The Company accounts for leases as operating or capital based on the criteria set forth in ASC 840-10-25-1. As of March 31, 2014, the Company had $206,917 in leased assets classified as Furniture, fixtures, and equipment and Manufacturing and lab equipment under Property and equipment in the Consolidated Balance Sheets. The accumulated depreciation on leased assets as of March 31, 2014 was $6,068. Short term capital lease liabilities of $68,094 are included as a component of current liabilities, and the long-term capital lease liabilities of $118,277 are included as a component of long term liabilities in our Consolidated Balance Sheets. Included in our capital lease liabilities as of March 31, 2014 are leases acquired during the Biozone acquisition of $112,705.
	As of March 31, 2014 and December 31, 2013, the Company had an outstanding balance on capital leases of $186,371 and $81,292, respectively. Future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (9 months)	$	60,650
	2015		80,867
	2016		69,017
	2017		4,155
	Total minimum lease payments		214,689
	Less amounts representing interest		-28,318
	Present value of minimum lease payments	$	186,371
	(C) Legal Matters
	From time to time, the Company is or may become involved in various legal proceedings that arise in the ordinary course of business or otherwise. Legal proceedings are subject to inherent uncertainties as to timing, outcomes, costs, expenses and time expenditures by the Company’s management and others on behalf of the Company. Although there can be no assurance, based on information currently available, the Company’s management believes that the outcome of legal proceedings that are pending or threatened against the Company will not have a material effect on the Company’s financial condition. However, the outcome of any of these matters is neither probable nor reasonably estimable.
	As of and for the three months ended March 31, 2014, the Company was not a party to any material litigation, and there were no lawsuits settled during the period.
	On March 27, 2014, Plaintiff 580 Garcia Properties, LLC, filed a lawsuit for unlawful detainer in California Superior Court in Contra Costa County, Case No. PS14-0407, against Defendants Biozone Laboratories, Inc., a California corporation, and Biozone Pharmaceuticals, Inc., a Nevada corporation (together, “Biozone”), represented by Paul Sievers of Manly, Stewart & Finaldi, and also against Defendants MusclePharm Corporation (“MPC”) and Biozone Laboratories, Inc., a Nevada corporation (“BLI-NV”), represented by King Parret & Droste LLP. The lawsuit seeks judicial determination of lease termination based on the landlords’ refusal to consent to lease assignment as well as incidental damages for alleged rental value even though rent payments are current, and attorney’s fees. On March 21, 2014 the Company received an eviction notice for our Biozone facility at 580 Garcia Avenue, Pittsburg, CA. The Company believes that this legal action is without merit and intends to defend this cause of action. However, if this matter is adversely determined against us, the Company is unable to quantify the amount of damages it would incur, including without limitation, moving expenses. The Company is entitled to indemnification from Biozone pursuant to the Asset Purchase Agreement, dated November 12, 2013, by and among MusclePharm Corporation, a Nevada corporation, Biozone Laboratories, Inc., a Nevada corporation, Biozone Pharmaceuticals, Inc., a Nevada corporation, Biozone Laboratories, Inc., a California corporation, Baker Cummins Corp. a Nevada corporation, and an indemnity agreement executed by Biozone in favor of the Company. The Company is entitled to bring indemnity claims against Biozone for this cause of action as well as other potential claims on or before the date which is nine months from January 2, 2014.
	(D) Product Liability
	As a manufacturer of nutritional supplements and other consumer products that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any material claims to date, it is possible that current and future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains product liability insurance with a deductible/retention of $10,000 per claim with an aggregate cap on retained loss of $5,000,000. At March 31, 2014, the Company had not recorded any accruals for product liabilities.
	(E) Sponsorship and Endorsement Contract Liabilities
	The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2017. The total value of outstanding payments as of March 31, 2014 was $14,536,916. The total outstanding payments are as follows:
	Outstanding Payments	2014		2015		2016		2017		Total
	Endorsement	$	1,461,000	$	2,455,833	$	853,333	$	-	$	4,770,166
	Sponsorship		3,521,250		4,832,500		1,125,000		100,000		9,578,750
	Service		128,000		60,000		-		-		188,000
	Total	$	5,110,250	$	7,348,333	$	1,978,333	$	100,000	$	14,536,916
	(F) SEC Investigation
	In July 2013, the Company received a formal order of investigation of the Company from the Denver Regional Office of the Securities and Exchange Commission. As a result of that formal order, the Company is conducting a review of its internal controls, disclosures of related party transactions, settlements of claims including share issuance, executive compensation, and disclosure of perquisites for the periods of 2010, 2011, and 2012. There can be no assurance that these are the only subject matters of concern, what the nature or amounts in question will be, or that these are the only periods under review

Defined_Contribution_Plan

Defined Contribution Plan	3 Months Ended
	Mar. 31, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 13: Defined Contribution Plan
	The Company established a 401(k) Plan (the “401(k) Plan”) for eligible employees of the Company. Generally, all employees of the Company who are at least twenty-one years of age and who have completed six months of entry service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make voluntary salary deferral contributions, on a pretax basis, of up to $17,500 for 2014 (subject to make-up contributions) in the form of voluntary payroll deductions. The Company may make discretionary contributions. During the three months ended March 31, 2014 and 2013, the Company’s matching contribution were $55,534 and $12,791, respectively.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 14: Related Party Transactions
	Ryan DeLuca, the Chief Executive Officer of one of our major customers, Bodybuilding.com, is the brother of Jeremy DeLuca, MusclePharm’s President of Sales and Marketing. We maintained a business relationship with Bodybuilding.com prior to hiring Mr. DeLuca. We do not offer preferential pricing of our products to Bodybuilding.com based on these relationships. Sales of products to Bodybuilding.com were $8,223,456 and $8,019,335 for the three months ended March 31, 2014 and 2013, respectively.  Bodybuilding.com owed the Company approximately $1,684,995 and $2,051,265 in trade receivables as of March 31, 2014 and December 31, 2013, respectively. The Company purchased marketing services from Bodybuilding.com during the three months ended March 31, 2014 in the amount of $349,998.
	We lease our office and warehouse facility in Hamilton, Ontario, Canada from 2017275 Ontario Inc., which is a company owned by Renzo Passaretti, VP and General Manager of MusclePharm Canada Enterprises Corp, our wholly owned Canadian subsidiary. For the three months ended March 31, 2014 and 2013, we paid rent of $18,064 and $19,502, respectively. The lease expires March 31, 2016.
	On October 16, 2013, the Company entered into an Office Lease Agreement with Frost Real Estate Holdings, LLC, a Florida limited liability company owned by Dr. Phillip Frost, one of our significant shareholders. Pursuant to the lease, the Company rents 1,437 square feet of office space for an initial term of three years, with an option to renew the lease for an additional three year term. For the three months ended March 31, 2014, we paid rent of $22,781.
	During the three months ended March 31, 2014, the Company purchased split dollar life insurance policies on certain key executives. These policies provide a split of 50% of the death benefit proceeds to the Company and 50% to the officer’s designated beneficiaries

Endorsement_Agreement

Endorsement Agreement	3 Months Ended
	Mar. 31, 2014
Endorsement Agreement [Abstract]	'
Endorsement Agreement [Text Block]	'
	Note 15: Endorsement Agreement
	On July 26, 2013, the Company entered into an Endorsement Licensing and Co-Branding Agreement by and among, the Company, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Under the terms of the Agreement, Mr. Arnold Schwarzenegger will co-develop a special Arnold Schwarzenegger product line and will be co-marketed under Mr. Schwarzenegger’s name and likeness.
	In connection with this agreement, the Company also issued Marine MP, LLC fully vested restricted shares of common stock. As of March 31, 2014 and December 31, 2013, the amount of unamortized stock compensation expense related to this agreement was $6,598,800 and $7,300,800, respectively. The shares are being amortized over the original three year term of the agreement. The current and non-current portions of this unamortized stock compensation are included as a component of Prepaid Stock Compensation in the Consolidated Balance Sheets.

Biozone_Acquisition

Biozone Acquisition	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Note 16: Biozone Acquisition
	On January 2, 2014, the Company closed the transactions contemplated in the Asset Purchase Agreement (the “APA”) dated November 12, 2013 with BioZone Pharmaceuticals, Inc. (“BioZone”) and its subsidiaries, BioZone Laboratories, Inc., and Baker Cummins Corporation (collectively, the “Seller”). At closing, the Company acquired substantially all of the operating assets of BioZone, including all assets associated with QuSomes, HyperSorb and EquaSomes drug delivery technologies and the name “Biozone”, “Biozone Laboratories” and similar names and domain names (and excluding certain assets including cash on hand).
	The base purchase price under the APA was 1.2 million shares of the Company’s common stock of which 600,000 shares were placed into escrow for a period of nine months to cover indemnification obligations and which shares are also subject to repurchase from the escrow for $10.00 per share in cash during the nine-month escrow period. The remaining 600,000 non-escrowed shares were issued to Biozone upon closing and are subject to a lockup agreement which permits private sales (subject to the lockup and certain leak out provisions). The total consideration paid by MSLP was $9,840,000 in common stock based on the stock price as of January 2, 2014. As of March 31, 2014 and the date of this report, the Company is still evaluating the extent to which there will be adjustments against the purchase price of the Biozone assets and liabilities as a result of certain claims that the Company may assert against Biozone pursuant to the indemnification provision under the APA and the 580 Garcia Lease indemnity agreement.
	All assets acquired from BioZone are now held in BioZone Laboratories, Inc., a wholly owned subsidiary of MusclePharm Corporation. Biozone is a developer, manufacturer, and marketer of over-the-counter drugs and preparations, cosmetics, and nutritional supplements.
		(A)	Assets and Liabilities Acquired
	The Biozone acquisition is considered the acquisition of a business and was accounted for under the purchase method of accounting. The acquired assets and liabilities have been recognized at their estimated fair value. MusclePharm contracted a third party valuation firm to determine the fair value at the date of purchase of all identifiable tangible and intangible assets purchased in the acquisition.
	The following reflects the allocation of the consideration to the net tangible and identifiable intangible assets of the Seller, based upon their estimated fair values:
	Assets and Liabilities at Fair Value
	Assets
	Intangible assets
	Patents		$	5,869,874
	Trademarks			656,160
	Customer Lists			629,607
	Domain Name			21
	Total intangible assets			7,155,662
	Property & equipment			1,859,066
	Receivables			806,212
	Inventory			840,999
	Other assets			577,453
	Total assets acquired			11,239,392
	Liabilities
	Factoring payable			795,031
	Trade payables			327,038
	Equipment leases			122,766
	Employee vacation liability			78,134
	Other			76,423
	Total liabilities assumed			1,399,392
	Total stock consideration		$	9,840,000
		(B)	Receivables
	We acquired various receivables as part of the asset acquisition of Biozone. The table below reflects the estimated fair value and the contractual value of the receivables as of the transaction date. As of the date of the acquisition we did not determine that any of the receivables would ultimately become uncollectible.
	Receivables		Estimated Fair		Contractual
			Value		Value
	Trade receivables		$	806,212	$	807,240
	Factoring receivable			150,702		151,016
	Asset sale receivable			399,814		400,000
		(C)	Unaudited Pro Forma Income Statement
	The accompanying consolidated statements of operations include the results of the Biozone Acquisition from the acquisition date of January 2, 2014.  The Company has determined that there were no significant transactions during the one day which is not presented in the accompanying consolidated statement of operations for the three months ended March 31, 2014 and has therefore not presented the pro forma effects of the acquisition for this period. The unaudited pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on January 1, 2013 is as follows:
	Three months ended March 31,		2013
	Total net revenues		$	24,436,698
	Net loss			-8,602,097
	Net loss per common share:
	Basic and Diluted		$	-2.08
	The above unaudited pro forma results include adjustments for amortization of acquired intangibles, interest expense and income tax expense.  The unaudited pro forma information as presented above is for informational purposes only and is not necessarily indicative of results of operations that would have been achieved if the acquisition had taken place at the date identified.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 17: Intangible Assets
	Intangible assets are as follows as of March 31, 2014, which also includes intangible assets acquired in the Biozone acquisition as more fully described in Note 16 above:
		As of March 31, 2014
		Gross carrying		Accumulated		Net carrying		Weighted
		amount		amortization		amount		average
								amortization
								period (years)
	Amortized intangible assets
	Patents	$	5,922,374	$	-220,482	$	5,701,892	8.74
	Trademarks		691,160		-38,467		652,693	7.36
	Customer relationships		629,607		-26,234		603,373	6
			7,243,141		-285,183		6,957,958
	Indefinite lived intangible assets
	Domain name		67,686		-		67,686	-
			67,686		-		67,686
	Total intangible assets	$	7,310,827	$	-285,183	$	7,025,644
	Estimated amortization expense for intangible assets as of March 31, 2014 is as follows:
	2014 (9 months)	$	830,703
	2015		1,104,106
	2016		1,001,226
	2017		932,310
	2018		910,413
	Thereafter		2,179,200
	Total amortization expense	$	6,957,958
	Intangible amortization expense for the three months ended March 31, 2014 was $285,183 and is included in operating expenses in the Consolidated Statement of Operations.
	With the exception of domain names, intangibles are amortized over the estimated useful lives of the assets of 2 to 18 years. We review intangible assets for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our intangible assets to be impaired during the three months ended March 31, 2014.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 18: Subsequent Events
	On April 2, 2014, the remaining 131,500 outstanding shares of our Series D Convertible Preferred Stock held by Dr. Philip Frost were converted into 263,000 shares of the Company’s common stock.
	On April 2, 2014, the Company entered into a security purchase agreement to sell the Fuse convertible note and warrants as more fully described in Notes 6 and 7 for an aggregate purchase price of $215,000.
	On April 8, 2014, Mr. L. Gary Davis submitted his resignation as the Company’s Chief Financial Officer, effective April 15, 2014, and as an employee of the Company entirely, effective December 31, 2014. Mr. Davis’ resignation was for personal reasons and not as a result of any disagreements between him and the Company with respect to the Company’s operations, policies or practices. Mr. Davis will continue to be employed by the Company in a special projects role until December 31, 2014; however, beginning on April 15, 2014 he will no longer be a named executive officer, including for purposes of the Securities Exchange Act of 1934, as amended.
	On April 10, 2014, Donald W. Prosser resigned from his position serving as a member of the Company’s Board of Directors, effective April 16, 2014. Mr. Prosser’s resignation from the Board of Directors was not as a result of any disagreements between him and the Company with respect to the Company’s operations, policies or practices. Also on April 10, 2014, Mr. Prosser was appointed to serve as the Company’s Chief Financial Officer and Principal Accounting Officer, effective April 16, 2014.
	Also on April 10, 2014, Bradley Pyatt resigned his position serving as President of the Company, effective April 16, 2014, but will continue to serve as the Company’s Chief Executive Officer and Chairman of its Board of Directors. Concurrently, Richard Estalella was appointed to serve as the Company’s President, effective April 16, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries MusclePharm Canada Enterprises Corp (“MusclePharm Canada”) and Biozone Laboratories, Inc. (“Biozone”). MusclePharm Canada began operations in April 2012, and Biozone began operations in January 2014. All intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.
Risks and Uncertainties [Policy Text Block]	'
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. At March 31, 2014 and December 31, 2013, the Company had no cash equivalents.
	The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.  At March 31, 2014 and December 31, 2013, we had two bank accounts that exceeded the federally insured limit.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Cash
	The Company segregates cash that is restricted in its use based on contractual provisions from unrestricted cash and cash equivalent balances. See Note 8(A) for further discussion on our March 31, 2014 restricted cash balance.
Accounts Receivable and Allowance For Doubtful Accounts [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet utilized by period end.
	Management performs ongoing evaluations of the Company’s customers’ financial condition and generally does not require collateral. Some international customers are required to pay for their orders in advance of shipment. Management reviews accounts receivable quarterly and reduces the carrying amount by a valuation allowance that reflects management’s best estimate of amounts that may not be collectible. Allowances, if any, for uncollectible accounts receivable are determined based upon information available and historical experience. Bad debt expense recognized as a result of our valuation allowance is classified under General and administrative expense in the Consolidated Statement of Operations.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices. The Company’s finance department contacts customers with past due balances to request payment.
	Accounts receivable consisted of the following at March 31, 2014 and December 31, 2013:
			As of March 31,			As of December 31,
			2014			2013
	Accounts receivable		$	20,274,972		$	14,830,487
	Less: allowance for discounts			-535,621			-1,060,000
	Less: allowance for doubtful accounts			-105,277			-29,307
	Accounts receivable – net		$	19,634,074		$	13,741,180
	At March 31, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable with customers:
	Customer		As of March 31, 2014				As of December 31, 2013
	A			22	%			16	%
	Bodybuilding.com (related party – See Note 14)			8	%			14	%
	C			6	%			24	%
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory is valued at the lower of cost or market value. Product-related inventory for MusclePharm and MusclePharm Canada is maintained using the First-In First-Out method, and inventory for Biozone is maintained using the average cost method. To estimate any necessary obsolescence or lower-of-cost-or-market adjustments, various assumptions are made in regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand, production planning and market conditions.
Prepaid Giveways [Policy Text Block]	'
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory sample items which are given away to aid in promotion of the brand.
Prepaid Sponsorship Fees [Policy Text Block]	'
	Prepaid Sponsorship and Endorsement Fees
	Prepaid sponsorship and endorsement fees represent fees paid in connection with Company sponsorships of certain events and trade shows as well as prepaid athlete endorsement fees, which are expensed over the period the fees are earned. A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts.  Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions.  Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract.  Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
Compensation Related Costs, Policy [Policy Text Block]	'
	Prepaid Stock Compensation
	Prepaid stock compensation represents amounts paid with stock for future contractual benefits to be received. The Company amortizes these contractual benefits over the life of the contracts using the straight-line method.
Prepaid Expenses [Policy Text Block]	'
	Prepaid Expenses
	Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include legal retainers, print advertising, insurance and service contracts requiring up-front payments.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in the Statements of Operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment. We review our property and equipment for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. An impairment loss is calculated by determining the difference between the carrying values and the estimated fair values of these assets. We did not consider any of our property and equipment to be impaired during the three months ended March 31, 2014 or 2013.
Debt Securities [Policy Text Block]	'
	Debt Securities
	The Company classifies its investment securities as either held-to-maturity, available-for-sale or trading. The Company’s debt securities are classified as trading securities and are carried at fair value with changes recognized through net income. See Note 6 for further discussion of the Company’s debt securities.
Accrued Liabilities [Policy Text Block]	'
	Accrued Liabilities
	Accrued liabilities consist of amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.
Debt, Policy [Policy Text Block]	'
	Debt
	The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 8 for further disclosure of debt liabilities.
Derivatives, Policy [Policy Text Block]	'
	Derivatives
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses Black-Scholes or lattice option-valuation models. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
	Once derivative instruments are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using a Black-Scholes or lattice option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid-in capital if redeemed or through earnings if forfeited or expired.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Payments
	Generally, all forms of share-based payments, including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.
Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]	'
	Revenue Recognition
	The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all of our Canadian sales, which represent 2% of total sales, recognition occurs upon shipment.
	The Company has determined that advertising related credits that were granted to customers fell within the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives). The guidance indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
	The Company records sales allowances and discounts as a direct reduction of sales. The Company grants volume incentive rebates to certain customers based on contractually agreed upon percentages once certain thresholds have been met. These volume incentive rebates are recorded as a direct reduction to sales.
	Sales for the three months ended March 31, 2014 and 2013 are as follows:
			Three Months Ended March 31,
			2014			2013
	Gross Sales		$	56,705,286		$	24,924,036
	Discounts			-6,495,832			-2,362,869
	Sales – Net		$	50,209,454		$	22,561,167
	The Company has an informal 7-day right of return for products. There were nominal returns under the Company’s informal right of return policy for the three months ended March 31, 2014 and 2013.
Major Customers, Policy [Policy Text Block]	'
	Significant Customers
	For the three months ended March 31, 2014 and 2013, the Company had the following concentrations of revenues with customers:
			Three Months Ended March 31,
	Customer		2014		2013
	Bodybuilding.com (related party – See Note 14)		15	%	33	%
	B		14	%	11	%
	A loss of either of these customers could have a material adverse impact on the Company.
Discounts And Sales Allowances Policy [Policy Text Block]	'
	Discounts and Sales Allowances
	We offer various discounts and sales allowances for volume rebate programs, product promotions, early payment remittances, and other discounts and allowances. We accrue for sales discounts and allowances over the period they are earned. Because of the inherent uncertainty surrounding volume rebate programs and product promotions that are based on sales thresholds, actual results could generate liabilities greater or less than the recorded amounts. Sales discounts and allowances for the three months ended March 31, 2014 and 2013 were $6.5 million, or 11% of gross sales, and $2.4 million of 9% of gross sales, respectively.
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Sales
	Cost of sales for MusclePharm and MusclePharm Canada represent costs directly related to the production, manufacturing and freight of the Company’s products purchased from third party manufacturers. For products produced by Biozone, cost of sales consists of costs for raw material, direct labor, freight expenses, and other supply and equipment rental expenses used to manufacture products.
Significant Vendors Policy [Policy Text Block]	'
	Significant Vendors
	The Company uses four non-affiliated principal manufacturers for the components of our products. We have an agreement in place with our primary manufacturer, which is in place to support our growth and ensure consistency in production and quality. During the three months ended March 31, 2014, our primary manufacturer accounted for approximately 54% of our product purchases and the next largest manufacturer accounted for 44% of product purchases. For the three months ended March 31, 2013, our primary manufacturer accounted for 97% of our product purchases.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and Handling
	We ship customer orders from our distribution center in Franklin, Tennessee. The facility is operated with the Company’s equipment and employees, and all inventory is owned by the Company. Shipments to customers from our distribution center are recorded as a component of cost of sales.
	The Company also uses a manufacturer in New York to manufacture one of the Company’s products. These orders are typically large and heavy and are drop shipped directly to our customers at the time of order. Costs associated with these shipments are recorded in cost of sales.
	For Canadian sales, the product is shipped from our Canadian warehouse to our customers. Costs associated with the shipments are recorded in cost of sales.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising
	Advertising and promotion expenses include digital and print advertising, trade show events, athletic endorsements and sponsorships, and promotional giveaways.  Advertising expenses are recognized in the month that the advertising appears while costs associated with trade show events are expensed when the event occurs.  For major trade shows, the expenses are recognized within the calendar year over the period in which we recognize revenue associated with sales generated at the trade show. Costs related to promotional giveaways are expensed when the product is either given out at a promotional event or shipped to the customer.
	A significant amount of the Company’s promotional expenses results from payments under endorsement and sponsorship contracts.  Accounting treatment for endorsement and sponsorship payments is based upon specific contract provisions.  Generally, endorsement payments are expensed straight-line over the term of the contract after giving recognition to periodic performance compliance provisions of the contract.  Prepayments made under the contracts are included in either current or long-term prepaid expenses depending on the period for which the prepayment applies.
	Some of the contracts provide for contingent payments to endorsers or athletes based upon specific achievement in their sports (e.g. winning a championship).  The Company records expense for these payments when the endorser achieves the specific achievement.
	Advertising expense for the three months ended March 31, 2014 and 2013, are as follows:
			Three Months Ended March 31,
			2014			2013
	Advertising and promotion		$	6,328,487		$	2,317,377
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Beginning with the adoption of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes, (included in FASB ASC Subtopic 740-10, Income Taxes — Overall), the Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three months ended March 31, 2014 and 2013.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings (Loss) Per Share
	Basic net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
	The Company uses the “treasury stock” method to determine whether there is a dilutive effect of outstanding option and warrant contracts. For the three months ended March 31, 2013 the Company reflected net loss and a dilutive net loss, and the effect of considering any common stock equivalents would have been anti-dilutive for the period. Therefore, separate computation of diluted earnings (loss) per share is not presented for the three months ended March 31, 2013.
	The Company has the following common stock equivalents as of March 31, 2014 and 2013, respectively:
			As of March 31,
			2014		2013
	Stock options (exercise price – $425/share)		472		670
	Warrants (exercise price – $4 - $1,275/share)		263,089		687,839
	Employee and director unvested shares		1,381,573		86,275
	Total common stock equivalents		1,645,134		774,784
	The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three months ended March 31, 2014 and 2013, respectively:
			Three months ended
			March 31,
			2014			2013
	Net income (loss)		$	2,736,234		$	-7,361,981
	Weighted average number of common shares outstanding			10,307,350			4,128,679
	Incremental shares from the assumed exercise of dilutive agreements			1,644,573			-
	Diluted common shares outstanding			11,951,923			4,128,679
	Earnings (loss) per shares - basic		$	0.27		$	-1.78
	Earnings (loss) per shares - diluted		$	0.23		$	-1.78
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency
	MusclePharm began operations in Canada in April 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are exchanged in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into the U.S. Dollar, which is the reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the period and the assets and liabilities at the end of period rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income and expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and held in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.
Reclassification, Policy [Policy Text Block]	'
	Reclassification
	The Company has reclassified certain prior period amounts to conform to the current period presentation. These reclassifications were for presentation purposes and had no effect on the financial position, results of operations, or cash flows for the periods presented.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In March 2013, the FASB issued ASU 2013-05, which indicates that the entire amount of a cumulative translation adjustment (CTA) related to an entity’s investment in a foreign entity should be released when one of the following occur:
		⋅	Sale of a subsidiary or group of net assets within a foreign entity and the sale represents the substantially complete liquidation of the investment in the foreign entity.
		⋅	Loss of a controlling financial interest in an investment in a foreign entity
		⋅	Step acquisition for a foreign entity
	The ASU does not change the requirement to release a pro rata portion of the CTA of the foreign entity into earnings for a partial sale of an equity method investment in a foreign entity. ASU 2013-5 is effective for fiscal years (and interim periods within those fiscal years) beginning on or after December 15, 2013. The adoption of this pronouncement did not have a material impact on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule Of Accounts Receivable [Table Text Block]	'
	Accounts receivable consisted of the following at March 31, 2014 and December 31, 2013:
		As of March 31,			As of December 31,
		2014			2013
	Accounts receivable	$	20,274,972		$	14,830,487
	Less: allowance for discounts		-535,621			-1,060,000
	Less: allowance for doubtful accounts		-105,277			-29,307
	Accounts receivable – net	$	19,634,074		$	13,741,180
Concentration Percentage Of Accounts Receivable With Customer [Table Text Block]	'
	At March 31, 2014 and December 31, 2013, the Company had the following concentrations of accounts receivable with customers:
	Customer	As of March 31, 2014				As of December 31, 2013
	A		22	%			16	%
	Bodybuilding.com (related party – See Note 14)		8	%			14	%
	C		6	%			24	%
Schedule Of Sales [Table Text Block]	'
	Sales for the three months ended March 31, 2014 and 2013 are as follows:
		Three Months Ended March 31,
		2014			2013
	Gross Sales	$	56,705,286		$	24,924,036
	Discounts		-6,495,832			-2,362,869
	Sales – Net	$	50,209,454		$	22,561,167
Schedule Of Concentrations Of Revenues With Customers [Table Text Block]	'
	For the three months ended March 31, 2014 and 2013, the Company had the following concentrations of revenues with customers:
		Three Months Ended March 31,
	Customer	2014		2013
	Bodybuilding.com (related party – See Note 14)	15	%	33	%
	B	14	%	11	%
Schedule Of Advertising Expense [Table Text Block]	'
	Advertising expense for the three months ended March 31, 2014 and 2013, are as follows:
		Three Months Ended March 31,
		2014			2013
	Advertising and promotion	$	6,328,487		$	2,317,377
Schedule Of Common Stock Equivalents [Table Text Block]	'
	The Company has the following common stock equivalents as of March 31, 2014 and 2013, respectively:
		As of March 31,
		2014		2013
	Stock options (exercise price – $425/share)	472		670
	Warrants (exercise price – $4 - $1,275/share)	263,089		687,839
	Employee and director unvested shares	1,381,573		86,275
	Total common stock equivalents	1,645,134		774,784
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three months ended March 31, 2014 and 2013, respectively:
		Three months ended
		March 31,
		2014			2013
	Net income (loss)	$	2,736,234		$	-7,361,981
	Weighted average number of common shares outstanding		10,307,350			4,128,679
	Incremental shares from the assumed exercise of dilutive agreements		1,644,573			-
	Diluted common shares outstanding		11,951,923			4,128,679
	Earnings (loss) per shares - basic	$	0.27		$	-1.78
	Earnings (loss) per shares - diluted	$	0.23		$	-1.78

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following at March 31, 2014 and December 31, 2013:
		As of March 31, 2014		As of December 31, 2013		Estimated Useful Life
	Leasehold improvements	$	3,205,922	$	619,159	From 20 to 182 months
	Furniture, fixtures and equipment		2,059,778		1,849,462	From 3 to 5 years
	Manufacturing and lab equipment		1,183,168		-	From 2 to 20 years
	Vehicles		444,065		442,300	From 2 to 5 years
	Displays		33,683		33,683	5 years
	Website		11,462		11,462	3 years
	Construction in process		190,373		1,018,509
	Total		7,128,451		3,974,575
	Less: Accumulated depreciation		-1,665,164		-1,360,991
		$	5,463,287	$	2,613,584

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventory consisted of the following at March 31, 2014 and December 31, 2013:
		March 31, 2014		December 31, 2013
	Raw materials inventory	$	661,026	$	-
	Work in process inventory		16,411		-
	Finished goods inventory		16,077,964		16,001,515
	Inventory reserve		-101,261		-229,147
	Total inventory - net	$	16,654,140	$	15,772,368

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
	The following are the major categories of assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):
		As of March 31,		As of December 31,
		2014		2013
	Assets
	Debt securities – FUSE convertible notes (Level 2)	$	215,000	$	259,715
	Derivative instruments – FUSE warrants (Level 2)		-		119,248
			215,000		378,963
	Liabilities
	Derivative liabilities - Series D shares (Level 2)	$	663,096	$	1,147,330

Debt_Securities_Tables

Debt Securities (Tables)	3 Months Ended
	Mar. 31, 2014
Investments, Debt and Equity Securities [Abstract]	'
Schedule of Debt Securities Activity [Table Text Block]	'
	The following table summarizes the Company’s debt securities activity for the three months ended March 31, 2014:
		Fuse Note
	Balance – December 31, 2013	$	259,715
	Redemption of note		-275,000
	Renewal of note		275,000
	Discount for value of conversion option		-206,855
	Accretion of net discount		222,140
	Unrealized loss on debt security		-60,000
	Balance – March 31, 2014	$	215,000

Derivative_Instruments_Tables

Derivative Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Derivative Assets at Fair Value [Table Text Block]	'
	The following table summarizes the Company’s derivative asset activity for the three months ended March 31, 2014:
	Balance – December 31, 2013	$	119,248
	Fair value of conversion option at renewal		206,855
	Unrealized loss		-326,103
	Balance – March 31, 2014	$	-

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule Of Long Term Debt [Table Text Block]	'
	At March 31, 2014 and December 31, 2013, debt consists of the following:
		As of March 31, 2014		As of December 31, 2013
	Revolving line of credit	$	2,500,000	$	2,500,000
	Auto loan - secured		-		2,902
	Unsecured debt		59,600		59,600
	Total debt		2,559,600		2,562,502
	Less: current portion		-2,559,600		-2,562,502
	Long term debt	$	-	$	-
Schedule Of Convertible Debt Activity And Terms [Table Text Block]	'
	Unsecured debt consisted of the following activity and terms:
	Balance - December 31, 2013	$	59,600
	Repayments		-
	Balance – March 31, 2014	$	59,600
Schedule Of Auto Loan Activity and Terms [Table Text Block]	'
	Vehicle loan account consisted of the following activity and terms:
				Interest Rate		Maturity
	Balance - December 31, 2013	$	2,902	6.99	%	3 payments of $1,008
	Repayments		-2,902
	Balance – March 31, 2014	$	-

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule Of Fair Value Of Derivative Instruments Conversion Feature [Table Text Block]	'
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2013		1,147,330
	Fair value mark to market adjustment for equity instruments		-484,234
	Derivative liability – March 31, 2014	$	663,096
Schedule Of Derivative Liabilities Fair Value Assumptions At Commitment and Re-Measurement Date [Table Text Block]	'
	The fair values at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2014:
			Commitment Date		Re-measurement Date
	Expected dividends		0	%	0	%
	Expected volatility		120	%	40	%
	Expected term:		1 year		1 year
	Risk free interest rate		0.14	%	0.13	%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

'

Schedule of Stockholders Equity [Table Text Block]

'

During the three months ended March 31, 2014, the Company issued the following common stock:

Transaction Type

Quantity

Valuation

Range of Value

(#)

($)

per Share

($)

Executive/board of director compensation

60,422

265,325

3.48 – 8.70

Stock issued for Biozone asset purchase

1,200,000

9,840,000

8.2

Total

1,260,422

10,105,325

3.48 – 8.70

Schedule Of Warrants Activity [Table Text Block]

'

A summary of warrant activity for the Company for the three months ended March 31, 2014 is as follows:

Number of Warrants

Weighted Average Exercise Price

Balance at December 31, 2013

263,089

4.43

Granted

-

-

Exercised

-

-

Converted

-

-

Balance at March 31, 2014

263,089

4.43

Warrants Outstanding

Warrants Exercisable

Range of

Number

Weighted Average

Weighted Average

Number

Weighted

Intrinsic Value

Exercise Prices

Outstanding

Remaining

Exercise Price

Exercisable

Average

Contractual Life (in

Exercise Price

years)

$

$4 - 1,275

263,089

1

$

4.43

263,089

$

4.43

$

518,295

Committments_Contingencies_and

Committments, Contingencies and Other Matters (Tables)	3 Months Ended
	Mar. 31, 2014
Operating Leased Assets [Line Items]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum annual lease payments for the above leases are approximately as follows:
	Years Ending December 31,
	2014 (9 months)	$	967,816
	2015		868,844
	2016		355,916
	2017		291,528
	2018		291,528
	Thereafter		3,206,808
	Total minimum lease payments	$	5,982,440
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	As of March 31, 2014 and December 31, 2013, the Company had an outstanding balance on capital leases of $186,371 and $81,292, respectively. Future minimum lease payments are as follows:
	Years Ending December 31,
	2014 (9 months)	$	60,650
	2015		80,867
	2016		69,017
	2017		4,155
	Total minimum lease payments		214,689
	Less amounts representing interest		-28,318
	Present value of minimum lease payments	$	186,371
Sponsorship and Endorsement Contract Liabilities [Member]	'
Operating Leased Assets [Line Items]	'
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	'
	The total value of outstanding payments as of March 31, 2014 was $14,536,916. The total outstanding payments are as follows:
	Outstanding Payments	2014		2015		2016		2017		Total
	Endorsement	$	1,461,000	$	2,455,833	$	853,333	$	-	$	4,770,166
	Sponsorship		3,521,250		4,832,500		1,125,000		100,000		9,578,750
	Service		128,000		60,000		-		-		188,000
	Total	$	5,110,250	$	7,348,333	$	1,978,333	$	100,000	$	14,536,916

Biozone_Acquisition_Tables

Biozone Acquisition (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	The following reflects the allocation of the consideration to the net tangible and identifiable intangible assets of the Seller, based upon their estimated fair values:
	Assets and Liabilities at Fair Value
	Assets
	Intangible assets
	Patents	$	5,869,874
	Trademarks		656,160
	Customer Lists		629,607
	Domain Name		21
	Total intangible assets		7,155,662
	Property & equipment		1,859,066
	Receivables		806,212
	Inventory		840,999
	Other assets		577,453
	Total assets acquired		11,239,392
	Liabilities
	Factoring payable		795,031
	Trade payables		327,038
	Equipment leases		122,766
	Employee vacation liability		78,134
	Other		76,423
	Total liabilities assumed		1,399,392
	Total stock consideration	$	9,840,000
Schedule of Business Combination Acquired Receivables [Table Text Block]	'
	As of the date of the acquisition we did not determine that any of the receivables would ultimately become uncollectible.
	Receivables	Estimated Fair		Contractual
		Value		Value
	Trade receivables	$	806,212	$	807,240
	Factoring receivable		150,702		151,016
	Asset sale receivable		399,814		400,000
Business Acquisition, Pro Forma Information [Table Text Block]	'
	The unaudited pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on January 1, 2013 is as follows:
	Three months ended March 31,	2013
	Total net revenues	$	24,436,698
	Net loss		-8,602,097
	Net loss per common share:
	Basic and Diluted	$	-2.08

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	'
	Intangible assets are as follows as of March 31, 2014, which also includes intangible assets acquired in the Biozone acquisition as more fully described in Note 16 above:
		As of March 31, 2014
		Gross carrying		Accumulated		Net carrying		Weighted
		amount		amortization		amount		average
								amortization
								period (years)
	Amortized intangible assets
	Patents	$	5,922,374	$	-220,482	$	5,701,892	8.74
	Trademarks		691,160		-38,467		652,693	7.36
	Customer relationships		629,607		-26,234		603,373	6
			7,243,141		-285,183		6,957,958
	Indefinite lived intangible assets
	Domain name		67,686		-		67,686	-
			67,686		-		67,686
	Total intangible assets	$	7,310,827	$	-285,183	$	7,025,644
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated amortization expense for intangible assets as of March 31, 2014 is as follows:
	2014 (9 months)	$	830,703
	2015		1,104,106
	2016		1,001,226
	2017		932,310
	2018		910,413
	Thereafter		2,179,200
	Total amortization expense	$	6,957,958

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accounting Policies [Line Items]	'	'
Accounts receivable	$20,274,972	$14,830,487
Less: allowance for discounts	-535,621	-1,060,000
Less: allowance for doubtful accounts	-105,277	-29,307
Accounts receivable - net	$19,634,074	$13,741,180

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	Mar. 31, 2014	Dec. 31, 2013
A [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration Percentage Of Accounts Receivable With Customers	22.00%	16.00%
Bodybuilding.com [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration Percentage Of Accounts Receivable With Customers	8.00%	14.00%
C [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration Percentage Of Accounts Receivable With Customers	6.00%	24.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Line Items]	'	'
Gross Sales	$56,705,286	$24,924,036
Discounts	-6,495,832	-2,362,869
Sales - Net	$50,209,454	$22,561,167

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 3)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Bodybuilding.com [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration percentage of revenue with customers	15.00%	33.00%
B [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration percentage of revenue with customers	14.00%	11.00%

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 4) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Line Items]	'	'
Advertising and promotion	$6,328,487	$2,317,377

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 5)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Line Items]	'	'
Total common stock equivalents	1,645,134	774,784
Employee Stock Option [Member]	'	'
Accounting Policies [Line Items]	'	'
Total common stock equivalents	472	670
Warrant [Member]	'	'
Accounting Policies [Line Items]	'	'
Total common stock equivalents	263,089	687,839
Employee and Director Unvested Shares [Member]	'	'
Accounting Policies [Line Items]	'	'
Total common stock equivalents	1,381,573	86,275

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details 6) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Line Items]	'	'
Net income (loss)	$2,736,234	($7,361,981)
Weighted average number of common shares outstanding (in shares)	10,307,350	4,128,679
Incremental shares from the assumed exercise of dilutive agreements (in shares)	1,644,573	0
Diluted common shares outstanding	11,951,923	4,128,769
Earnings (loss) per shares - basic (in dollars per share)	$0.27	($1.78)
Earnings (loss) per shares - diluted (in dollars per share)	$0.23	($1.78)

Recovered_Sheet1

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Line Items]	'	'
Stock Option Exercised Price Per Share (in dollars per share)	$425	$425
Minimum Warrants Exercised Price Per Share (in dollars per share)	$4	$4
Maximum Warrants Exercised Price Per Share (in dollars per share)	$1,275	$1,275
Sales Discounts, Returns and Allowances, Goods, Total	$6,500,000	$2,400,000
Earnings Per Share, Basic and Diluted	'	($1.78)
Sales Discounts Returns and Allowances Goods Percentage on Gross Sales	11.00%	9.00%
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$0	$0
Primary Manufacturer [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration Risk, Percentage	54.00%	97.00%
Largest Manufacturer [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration Risk, Percentage	44.00%	'
Canadian Sales [Member]	'	'
Accounting Policies [Line Items]	'	'
Concentration Risk, Percentage	2.00%	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Total	$7,128,451	$3,974,575
Less: Accumulated depreciation	-1,665,164	-1,360,991
Property, Plant and Equipment, Net	5,463,287	2,613,584
Furniture, Fixtures And Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	2,059,778	1,849,462
Furniture, Fixtures And Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'3 years	'
Furniture, Fixtures And Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'5 years	'
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	3,205,922	619,159
Leasehold Improvements [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'20 months	'
Leasehold Improvements [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'182 months	'
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	444,065	442,300
Vehicles [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'2 years	'
Vehicles [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'5 years	'
Displays [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	33,683	33,683
Property, Plant and Equipment, Estimated Useful Life (in years)	'5 years	'
Website [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	11,462	11,462
Property, Plant and Equipment, Estimated Useful Life (in years)	'3 years	'
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	190,373	1,018,509
Manufacturing and lab equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	$1,183,168	$0
Manufacturing and lab equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'2 years	'
Manufacturing and lab equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Life (in years)	'20 years	'

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Raw materials inventory	$661,026	$0
Work in process inventory	16,411	0
Finished goods inventory	16,077,964	16,001,515
Inventory reserve	-101,261	-229,147
Total inventory - net	$16,654,140	$15,772,368

Inventory_Details_Textual

Inventory (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Inventory, Finished Goods, Gross	$16,077,964	$16,001,515
Third Party Manufacturers [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Finished Goods, Gross	$16,039,948	'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets	'	'
Debt securities - FUSE convertible notes (Level 2)	$215,000	$259,715
Derivative instruments - FUSE warrants (Level 2)	0	119,248
Assets, Fair Value Disclosure, Total	215,000	378,963
Liabilities	'	'
Derivative liabilities - Series D shares (Level 2)	$663,096	$1,147,330

Debt_Securities_Details

Debt Securities (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Unrealized loss on debt security	($60,000)	$0
Fuse Note [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Balance - December 31, 2013	259,715	'
Redemption of note	-275,000	'
Renewal of note	275,000	'
Discount for value of conversion option	-206,855	'
Accretion of net discount	222,140	'
Unrealized loss on debt security	-60,000	'
Balance - March 31, 2014	$215,000	'

Debt_Securities_Details_Textua

Debt Securities (Details Textual) (USD $)	3 Months Ended				1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 11, 2013	Nov. 07, 2013	Jan. 31, 2014	Nov. 30, 2013	Jan. 03, 2014	Nov. 07, 2013
				secured convertible promissory note [Member]	secured convertible promissory note [Member]	secured convertible promissory note [Member]	secured convertible promissory note [Member]	secured convertible promissory note [Member]
				Biozone Convertible Note [Member]	Fuse Convertible Note [Member]	Fuse Convertible Note [Member]	Fuse Convertible Note [Member]	Fuse Convertible Note [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Notes, Loans and Financing Receivable, Net, Current, Total	'	'	'	$200,000	'	'	$275,000	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	10.00%	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	'	13,750,000	3,076,923	'	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	'	'	$0.02	$0.07
Equity Method Investment, Ownership Percentage	'	'	'	'	'	'	'	9.99%
Discount For Value Of Derivative Instrument	206,855	174,574	'	'	'	'	'	'
Debt Instrument Additional Fund Amount	'	'	$75,000	'	'	'	'	'
Debt Instrument, Maturity Date	'	'	'	'	3-Jan-19	'	'	'

Derivative_Instruments_Details

Derivative Instruments (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Trading Activity, Gains and Losses, Net [Line Items]	'
Balance - December 31, 2013	$119,248
Fair value of conversion option at renewal	206,855
Unrealized loss	-326,103
Balance - March 31, 2014	$0

Derivative_Instruments_Details1

Derivative Instruments (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014
Derivatives, Fair Value [Line Items]	'
Conversion option at renewal Debt Securities Converted	$206,855
Fuse Warrants [Member]	'
Derivatives, Fair Value [Line Items]	'
Payments to Acquire Trading Securities Held-for-investment	$174,574
secured convertible promissory note [Member] | Fuse Warrants [Member]	'
Derivatives, Fair Value [Line Items]	'
Debt Conversion, Converted Instrument, Shares Issued	9,165,750
Investment Warrants, Exercise Price	$0.07
Warrants Expiration Term	'5 years

Debt_Details

Debt (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Capitalization, Long-term Debt [Line Items]	'	'
Revolving line of credit	$2,500,000	$2,500,000
Auto loan - secured	0	2,902
Unsecured debt	59,600	59,600
Total debt	2,559,600	2,562,502
Less: current portion	-2,559,600	-2,562,502
Long term debt	$0	$0

Debt_Details_1

Debt (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Debt Instrument [Line Items]	'
Balance - December 31, 2013	$59,600
Repayments	0
Balance - March 31, 2014	$59,600

Debt_Details_2

Debt (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
			Vehicle Loan [Member]
Debt Instrument [Line Items]	'	'	'
Balance	$0	$2,902	$2,902
Repayments	'	'	-2,902
Balance	$0	$2,902	$0
Interest Rate	'	'	6.99%
Maturity	'	'	'3 payments of $1,008

Debt_Details_Textual

Debt (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 24, 2013
Debt Instrument [Line Items]	'	'	'
Debt Default, Short-term Debt, Amount	$59,600	$59,600	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	2,500,000
Line of Credit Facility, Expiration Date	15-Sep-14	'	'
Line of Credit Facility, Interest Rate Description	'prime plus 2%	'	'
Line of Credit Facility, Interest Rate at Period End	5.25%	'	'
U.S. Bank, N.A D Savings Deposits [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Restricted Cash and Investments, Current, Total	$2,500,000	'	'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Derivative Liabilities [Line Items]	'
Derivative liability - December 31, 2013	$1,147,330
Fair value mark to market adjustment for equity instruments	-484,234
Derivative liability - March 31, 2014	$663,096

Derivative_Liabilities_Details1

Derivative Liabilities (Details 1)	3 Months Ended
	Mar. 31, 2014
Commitment Date [Member]	'
Derivative Liabilities [Line Items]	'
Expected dividends	0.00%
Expected volatility	120.00%
Expected term:	'1 year
Risk free interest rate	0.14%
Re Measurement Date [Member]	'
Derivative Liabilities [Line Items]	'
Expected dividends	0.00%
Expected volatility	40.00%
Expected term:	'1 year
Risk free interest rate	0.13%

Derivative_Liabilities_Details2

Derivative Liabilities (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Derivative Liabilities [Line Items]	'	'
Derivative expense	$0	$96,913

Restricted_Stock_Units_Details

Restricted Stock Units (Details Textual) (USD $)	3 Months Ended			1 Months Ended			3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Nov. 30, 2012	Jun. 30, 2013	Jun. 30, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
		December 31, 2015 [Member]	Chief Operating Officer [Member]	Chief Financial Officer [Member]	key employees officers and directors [Member]	key employees officers and directors [Member]	key employees officers and directors [Member]	Director [Member]	Director [Member]	Director [Member]
		Subsequent Event [Member]				Restricted Stock [Member]	Restricted Stock [Member]	Restricted Stock [Member]	Restricted Stock [Member]	Restricted Stock [Member]
										December 31, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Issued For Services (in shares)	'	'	'	129,413	'	'	'	'	'	'
Stock Issued During Period, Value, Issued For Services	'	'	'	$449,900	'	'	'	'	'	'
Shares Vesting In Next Twelve Months Number	'	'	43,137	'	'	'	'	'	'	'
Shares Vesting In Year Two Number	'	'	43,138	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	'	'	86,275	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized	11,342,915	'	112,989	'	'	'	'	240,000	'	113,998
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	'	'	'	1,550,000	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	'	'	'	1,500,200	16,284	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	'	'	'	'	16,517,202	'	'	'	'
Stock Issued During Period, Value, Restricted Stock Award, Gross	'	'	'	'	17,065,500	'	'	320,007	152,000	'
Restricted stock agreement grant vesting percentage	17.00%	83.00%	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares	'	'	'	'	'	'	263,500	'	'	'
Share-based Compensation, Total	$2,402,435	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	'	'	'	'	'	'	'	48,856	19,364	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Class of Stock [Line Items]	'
Executive/Board of Director compensation, Quantity	60,422
Executive/Board of Director compensation, Valuation	$265,325
Stock issued for Biozone asset purchase, Quantity	1,200,000
Stock issued for Biozone asset purchase, Valuation	9,840,000
Stock issued for Biozone asset purchase, Range of value per share	$8.20
Total, Quantity	1,260,422
Total, Valuation	$10,105,325
Minimum [Member]	'
Class of Stock [Line Items]	'
Executive/Board of Director compensation, Range of Value per share	$3.48
Total, Range of Value per Share	$3.48
Maximum [Member]	'
Class of Stock [Line Items]	'
Executive/Board of Director compensation, Range of Value per share	$8.70
Total, Range of Value per Share	$8.70

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Class of Stock [Line Items]	'
Warrants Exercisable, Numbers Exercisable (in shares)	263,089
Minimum [Member]	'
Class of Stock [Line Items]	'
Weighted Average Exercise Price, Balance (in dollars per share)	$4
Maximum [Member]	'
Class of Stock [Line Items]	'
Weighted Average Exercise Price, Balance (in dollars per share)	$1,275
Warrant [Member]	'
Class of Stock [Line Items]	'
Number of Warrants, Outstanding Balance (in shares)	263,089
Number of Warrants, Granted (in shares)	0
Number of Warrants, Exercised/settled (in shares)	0
Number of Warrants, Converted (in shares)	0
Number of Warrants, Outstanding Balance (in shares)	263,089
Weighted Average Exercise Price, Balance (in dollars per share)	$4.43
Weighted Average Exercise Price, Granted (in dollars per share)	$0
Weighted Average Exercise Price, Exercised/settled (in dollars per share)	$0
Weighted Average Exercise Price, Converted (in dollars per share)	$0
Weighted Average Exercise Price, Balance (in dollars per share)	$4.43
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	'1 year
Warrants Exercisable, Weighted Average Exercise Price (in dollars per share)	$4.43
Warrants Exercisable, Intrinsic Value	$518,295
Warrant Outstanding Weighted Average Exercise Price	$4.43
Warrant Outstanding Number Outstanding	263,089

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Feb. 04, 2013	Jan. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
			Board of Directors Chairman [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]
Stockholders Equity Disclosure [Line Items]	'	'	'	'	'	'	'
Description Of Class Of Stock Provision	'	'	'	'	'The shares of Series D have the following provisions: · Voting rights based on number of common shares of conversion option; · Initially no rights to dividends; · Liquidation rights entitle the receipt of net assets on a pro-rata basis; and · Convertible into 2 shares of common stock, subject to adjustment.	'	'
Stock Repurchased During Period, Value	'	'	$5,000,000	'	'	'	'
Stock Repurchased Maximum Value	'	'	5,000,000	'	'	'	'
Preferred stock, shares authorized	'	'	'	'	1,600,000	1,600,000	1,600,000
Number Of Shares Sold Under Subscription Agreement	'	'	'	1,500,000	'	'	'
Proceeds from Issuance of Preferred Stock and Preference Stock	$0	$12,000,000	'	$12,000,000	'	'	'

Commitments_Contingencies_and_1

Commitments, Contingencies and Other Matters (Details) (USD $)	Mar. 31, 2014
Years Ending December 31,	'
2014 (9 months)	$967,816
2015	868,844
2016	355,916
2017	291,528
2018	291,528
Thereafter	3,206,808
Total minimum lease payments	$5,982,440

Commitments_Contingencies_and_2

Commitments, Contingencies and Other Matters (Details 1) (USD $)	Mar. 31, 2014
Years Ending December 31,	'
2014 (9 months)	$60,650
2015	80,867
2016	69,017
2017	4,155
Total minimum lease payments	214,689
Less amounts representing interest	-28,318
Present value of minimum lease payments	$186,371

Commitments_Contingencies_and_3

Commitments, Contingencies and Other Matters (Details 2) (USD $)	Mar. 31, 2014
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
Total	$14,536,916
Sponsorship and Endorsement Contract Liabilities [Member]	'
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	5,110,250
2015	7,348,333
2016	1,978,333
2017	100,000
Total	14,536,916
Endorsement [Member] | Sponsorship and Endorsement Contract Liabilities [Member]	'
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	1,461,000
2015	2,455,833
2016	853,333
2017	0
Total	4,770,166
Sponsorship [Member] | Sponsorship and Endorsement Contract Liabilities [Member]	'
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	3,521,250
2015	4,832,500
2016	1,125,000
2017	100,000
Total	9,578,750
Service [Member] | Sponsorship and Endorsement Contract Liabilities [Member]	'
Contractual Obligation, Fiscal Year Maturity [Line Items]	'
2014	128,000
2015	60,000
2016	0
2017	0
Total	$188,000

Commitments_Contingencies_and_4

Commitments, Contingencies and Other Matters (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Commitments And Contingency [Line Items]	'	'	'
Operating Lease Expire Term	'2029	'	'
Operating Leases, Rent Expense, Net	$297,497	$151,219	'
Product Liability Insurance Deduction	10,000	'	'
Aggregate Product Liability Retained Loss	5,000,000	'	'
Capital Lease Obligations, Current	68,094	'	'
Capital Lease Obligations, Noncurrent	118,277	'	'
Capital Lease Obligations	186,371	'	81,292
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total	206,917	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	'	'	6,068
Contractual Obligation, Total	14,536,916	'	'
Sponsorship and Endorsement Contract Liabilities [Member]	'	'	'
Commitments And Contingency [Line Items]	'	'	'
Operating Lease Expire Term	'2017	'	'
Contractual Obligation, Total	14,536,916	'	'
Biozone [Member]	'	'	'
Commitments And Contingency [Line Items]	'	'	'
Capital Lease Obligations	$112,705	'	'

Defined_Contribution_Plan_Deta

Defined Contribution Plan (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Defined Contribution Pension And Other Postretirement Plans Disclosure [Line Items]	'	'
Noncash Contribution Expense	$17,500	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$55,534	$12,791

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	3 Months Ended					3 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Oct. 16, 2013	Mar. 31, 2014	Mar. 31, 2013
			Bodybuilding.com [Member]	Bodybuilding.com [Member]	Bodybuilding.com [Member]	Frost Real Estate Holdings, LLC [Member]	Frost Real Estate Holdings, LLC [Member]	VP and General Manager [Member]	VP and General Manager [Member]
							sqft
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Revenue from Related Parties	'	'	$8,223,456	$8,019,335	'	'	'	'	'
Due from Related Parties	'	'	1,684,995	'	2,051,265	'	'	'	'
Securities Purchase Under Agreement Description	'The Company purchased marketing services from Bodybuilding.com during the three months ended March 31, 2014 in the amount of $349,998.	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense, Net	$297,497	$151,219	'	'	'	$22,781	'	$18,064	$19,502
Lease Expiration Date	31-Mar-16	'	'	'	'	'	'	'	'
Area of Land	'	'	'	'	'	'	1,437	'	'
Deferred Compensation Arrangements, Overall, Description	'the Company purchased split dollar life insurance policies on certain key executives. These policies provide a split of 50% of the death benefit proceeds to the Company and 50% to the officers designated beneficiaries	'	'	'	'	'	'	'	'

Endorsement_Agreement_Details_

Endorsement Agreement (Details Textual) (Marine MP LLC [Member], USD $)	Mar. 31, 2014	Dec. 31, 2013
Marine MP LLC [Member]	'	'
Endorsement Agreement Disclosure [Line Items]	'	'
Prepaid Expense	$6,598,800	$7,300,800

Biozone_Acquisition_Details

Biozone Acquisition (Details) (USD $)	Mar. 31, 2014
Intangible assets	'
Total intangible assets	$7,155,662
Property & equipment	1,859,066
Receivables	806,212
Inventory	840,999
Other assets	577,453
Total assets acquired	11,239,392
Liabilities	'
Factoring payable	795,031
Trade payables	327,038
Equipment leases	122,766
Employee vacation liability	78,134
Other	76,423
Total liabilities assumed	1,399,392
Total stock consideration	9,840,000
Patents [Member]	'
Intangible assets	'
Total intangible assets	5,869,874
Trademarks [Member]	'
Intangible assets	'
Total intangible assets	656,160
Customer Relationships [Member]	'
Intangible assets	'
Total intangible assets	629,607
Domain name [Member]	'
Intangible assets	'
Total intangible assets	$21

Biozone_Acquisition_Details_1

Biozone Acquisition (Details 1) (USD $)	Mar. 31, 2014
Trade Accounts Receivable [Member]	'
Business Acquisition [Line Items]	'
Fair Value	$806,212
Contractual Value	807,240
Factoring receivable [Member]	'
Business Acquisition [Line Items]	'
Fair Value	150,702
Contractual Value	151,016
Asset sale receivable [Member]	'
Business Acquisition [Line Items]	'
Fair Value	399,814
Contractual Value	$400,000

Biozone_Acquisition_Details_2

Biozone Acquisition (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2013
Business Acquisition [Line Items]	'
Total net revenues	$24,436,698
Net loss	($8,602,097)
Net loss per common share:	'
Basic and Diluted	($2.08)

Biozone_Acquisition_Details_Te

Biozone Acquisition (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014
Business Acquisition [Line Items]	'
Stock Issued During Period, Shares, Acquisitions	1,200,000
Escrow Period	'0 months
Business Acquisition, Share Price	$10
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued	9,840,000
Escrow [Member]	'
Business Acquisition [Line Items]	'
Stock Issued During Period, Shares, Acquisitions	600,000
Non-escrowed [Member]	'
Business Acquisition [Line Items]	'
Stock Issued During Period, Shares, Acquisitions	600,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			Domain name [Member]	Patents [Member]	Trademarks [Member]	Customer Relationships [Member]
Intangible Assets [Line Items]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Gross	$7,243,141	'	'	$5,922,374	$691,160	$629,607
Indefinite-Lived Intangible Assets (Excluding Goodwill)	67,686	'	67,686	'	'	'
Intangible Assets, Gross (Excluding Goodwill), Total	7,310,827	'	'	'	'	'
Finite-Lived Intangible Assets, Accumulated Amortization	-285,183	'	'	-220,482	-38,467	-26,234
Finite-Lived Intangible Assets, Net, Total	6,957,958	'	'	5,701,892	652,693	603,373
Intangible Assets, Net (Excluding Goodwill), Total	$7,025,644	$155,165	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'8 years 8 months 26 days	'7 years 4 months 10 days	'6 years

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Mar. 31, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Line Items]	'
2014 (9 months)	$830,703
2015	1,104,106
2016	1,001,226
2017	932,310
2018	910,413
Thereafter	2,179,200
Total amortization expense	$6,957,958

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$285,183	$0
Minimum [Member]	'	'
Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'2 years	'
Maximum [Member]	'	'
Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'18 years	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	0 Months Ended
	Apr. 02, 2014
Subsequent Event [Line Items]	'
Sale Of Convertible Notes And Warrants	$215,000
Common Stock [Member]	'
Subsequent Event [Line Items]	'
Conversion of Stock, Shares Issued	263,000
Series D Convertible Preferred Stock [Member]	'
Subsequent Event [Line Items]	'
Conversion of Stock, Shares Converted	131,500